Edition:
United States

Aclaris Therapeutics Inc (ACRS.OQ)

ACRS.OQ on NASDAQ Stock Exchange Global Select Market

13.41USD
15 Oct 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$13.41
Open
$13.53
Day's High
$13.60
Day's Low
$13.25
Volume
54,500
Avg. Vol
81,820
52-wk High
$27.08
52-wk Low
$12.84

Chart for

About

Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and... (more)

Overall

Beta: --
Market Cap(Mil.): $828.20
Shares Outstanding(Mil.): 30.00
Dividend: --
Yield (%): --

Financials

  ACRS.OQ Industry Sector
P/E (TTM): -- 85.91 32.75
EPS (TTM): -2.03 -- --
ROI: -38.27 1.70 14.60
ROE: -38.37 3.17 16.33

BRIEF-Aclaris Therapeutics Q1 Loss Per Share $0.98

* ACLARIS THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS

May 08 2018

BRIEF-Aclaris Therapeutics Announces Availability Of Eskata In The U.S.

* ACLARIS THERAPEUTICS ANNOUNCES AVAILABILITY OF ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W)

May 07 2018

BRIEF-Aclaris Therapeutics Names Bryan Reasons Director And Chairman, Audit Committee

* ACLARIS THERAPEUTICS ANNOUNCES APPOINTMENT OF BRYAN REASONS AS A DIRECTOR AND CHAIRMAN OF THE AUDIT COMMITTEE Source text for Eikon: Further company coverage:

Apr 24 2018

Competitors

  Price Chg
RXi Pharmaceuticals Corp (RXII.OQ) $0.45 -0.00

Earnings vs. Estimates